Throughout the developing world, access to antiretroviral therapy (ART) for treatment of HIV infections is increasing. As a consequence, drug-resistant HIV (HIVDR) is emerging and diminishing treatment options. In developing countries, first-line options for treatment are limited, second-line treatment regimens are much more expensive than first-line drugs, and the opportunity to perform drug-resistance genotyping is restricted (1). In Latin America, there are a number of studies of secondary drug resistance, initial drug resistance (IDR), and primary or transmitted drug resistance (TDR) (2-15), but discerning continental trends for antiretroviral (ARV) resistance in this region is complex. 
Prolonging the lifetimes of ARVs is vital to the sustainability of HIV treatment programs in developing nations (1). Recommendations for limiting HIVDR in resource-limited countries are defined in the World Health Organization (WHO) global strategy for prevention and assessment of HIVDR (16) . Surveillance of HIV TDR in recently infected individuals is key to the WHO strategy (16) .
HIV/AIDS was first observed in Panama in 1984. There are approximately 20 000 HIV-positive persons in a concentrated epidemic (17) and there have been a total of 10 381 AIDS cases since 1984. 5 In 2006, 0.5% of pregnant women were HIV positive, and the share dropped to 0.3% for [2007] [2008] [2009] . 5 Panama has provided free diagnosis, monitoring, and ART to 70.0% of all eligible patients since 1999 and to all patients since 2001 (18) . Currently, 4 463 (19) First-line ART for adults in Panama follows WHO guidelines (20) : one nonnucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, combined with two nucleoside analog reverse transcriptase inhibitors (NRTIs), for which recommendations have recently changed (21, 22) . Since 2007, NRTIs were lamivudine (3TC) and zidovudine (AZT) (21) and, since July 2011, tenofovir with 3TC or emtricitabine. Current recommendations for second-line therapy are two NRTIs with a ritonavir-boosted protease inhibitor, usually lopinavir (22) . Since 2007, Panama's ART to prevent motherto-child-transmission has involved AZT and 3TC, with lopinavir (21, 22) . From 2007 to July 2011, ART for infants born to HIV-positive mothers was AZT until 6 weeks of age (21) . Current guidelines recommend this regimen only for babies born to mothers receiving ART prenatally and perinatally (22) . Babies born to mothers not taking ART prenatally and perinatally should receive AZT, 3TC, and nevirapine (22) .
Despite broad and prolonged ART coverage in Panama, few studies have examined HIVDR prevalence (2) and there are no reports of HIV TDR from horizontal or vertical transmission. HIVDR studies in this country are important, but financial, human, and laboratory capacities to manage HIVDR are limited in developing countries. In recognition of this problem and as a pillar of the WHO global strategy against HIVDR (16) , the WHO Threshold Survey (WHO-TS) surveillance and classification strategy was developed (23, 24) . WHO-TS allows for low-cost classification of the prevalence of HIV TDR in adults to individual drugs or drug classes as low (< 5.0%), moderate (5.0%-15.0%), or high (> 15.0%) (24) .
Forty-one WHO-TS studies have been conducted in Africa, Asia, and Mexico (1, 23, [25] [26] [27] [28] [29] [30] [31] [32] . 6 An adaptation of the WHO-TS strategy was used in Brazil (33) . Combined analysis of WHO-TS from 20 countries showed a low overall level of HIV TDR (3.7%), although 17.0% of surveys showed moderate levels of HIV TDR (1). In Central America, the WHO-TS has not been applied.
Our first objective is to apply WHO-TS, with modifications, to investigate HIV TDR among Panamanian adults. For the second objective, we investigate IDR in Panama, for the first time at the molecular level (34) . While WHO clearly describes its goal in surveying IDR (35) , it does not have a formal IDR surveillance strategy.
MATERIALS AND METHODS

WHO-TS methodology and its adaptations
The WHO-TS strategy (23, 24) focuses on regions where ART has been available to ≥ 20.0% of eligible individuals for ≥ 3 years; this study focuses on Panama City. WHO-TS methodology requires collection and analysis of 47 eligible specimens, preferably within 12 months. October 2010 at the clinic of the Gorgas  Memorial Institute for Health Studies  (ICGES) , where all HIV patients in Panama City were referred for baseline viral load measurement after their initial HIV diagnoses elsewhere.
Samples were collected March 2008 to
In this descriptive study, plasma samples for 47 HIV-positive, ART-naive adults from the general population were collected and genotyped for drug resistance at ICGES and their resistance levels were evaluated (24) . A median of 3 months had elapsed between initial HIV diagnosis and genotyping. Mean CD4 + count was 400 cells per μL. At ICGES, two of the WHO-TS mandatory eligibility criteria for patient inclusion were met: laboratory confirmation of HIVpositive status and, if female, no previous pregnancies (23) . The third criterion, patient age < 25 years, was extended to ≤ 26 years: patients ≥ 25 years had a confirmed HIV-negative serology in the previous 3 years. The sample collection period was extended from the recommended 12 months. 
Infant samples
Genotyping methods
An in-house method was used to genotype and analyze reverse transcriptase and protease genes for specific mutations associated with drug resistance in HIV-1. HIV-1 RNA was extracted with the QIAamp viral RNA mini kit (Qiagen) and reverse-transcribed, amplified, and sequenced with the primers indicated in 
Ethics approval and patient consent
Panama's National Institutional Review Board approved this study as part of the ICGES HIV Epidemiology Study (RV165) and informed consent regarding sample use was obtained.
RESULTS
Adults
Forty-seven HIV-positive men (n = 30) and women (n = 17), aged 16-26 years (mean 21.6 years), all residing in Panama City, were included (Table 2) . Six patients showed one or more mutations associated with TDR: one patient showed multiple mutations associated with NNRTI resistance (patient 3) and another showed multiple resistanceassociated mutations against NRTIs and NNRTIs (patient 15). The prevalence of TDR mutations overall and against NRTIs and NNRTIs was moderate (5.0%-15.0%). The prevalence of TDR mutations against protease inhibitors was low (< 5.0%) ( Table 2) . Polymorphisms not associated with drug resistance were also observed (Table 2) .
Neonates and infants
Twenty-five blood samples from male (n = 12) and female (n = 13) patients aged between 9 days and 1 year were collected (Table 3) 
DISCUSSION
The WHO-TS guidelines were adapted to investigate HIV TDR in Panamanian adults. The overall prevalence was moderate and justifies more advanced surveillance for drug-resistant HIV among newly infected patients, especially from groups at high risk of HIV infection.
The prevalence of TDR mutations against protease inhibitors (< 5.0%) and NRTIs and NNRTIs (5.0%-15.0%) in Panama is similar to findings from a Brazilian adaptation of the WHO-TS, reporting a moderate level of HIV TDR (33) , and to other regional HIV TDR studies: low to moderate HIV TDR has been identified in Argentina (2.4%-8.8%), Bra zil (4.2%-11.0%), Chile (1.7%-12.0%), Colombia (5.8%), the Dominican Republic (7.8%) (7), Honduras (7.0%) (5), Peru (3.0%-3.4%), and Venezuela (3.2%-11.0%) (41) . In the region, therefore, Panama's prevalence classification is not unusual, but Latin America's overall rates of HIV TDR appear to be higher than in Africa and Asia, according to the combined analysis of WHO-TS from 20 African and Asian countries (1). This general conclusion justifies closer surveillance of HIV TDR in the region and adoption of methodologic adaptations, which will increase Latin American participation in the WHO-TS.
Panama's moderate levels of HIV TDR reflect 10 years of using ART and the types of ART available. K103N, P225H, and Y181C mutations alter the effectiveness of efavirenz, which is used as a first-line drug for nonpregnant Panamanians; I85V is associated, in ART-naive patients, with resistance to atazanavir (42), a second-line ART in Panama (21); and M41L and T215F reduce the susceptibility of HIV-1 to stavudine and AZT, first-line drugs in Panama for pregnant women and newborns and formerly for adults and young people. M41L, one of the few transmitted mutations not observed to revert over time (43) , was seen in four patients. Its high prevalence is particularly important in Panama: until July 2011, first-line therapy was efavirenz with AZT and 3TC, a regimen whose efficacy would have been compromised by a high prevalence of the M41L mutation, but the therapy has since changed to efavirenz, tenofovir with 3TC, or emtricitabine, a regimen compromised only by the M41L mutation combined with other thymidine analog mutations. 7 The prevalence of TDR mutations found here agrees with our work showing that mutations associated with resistance to NRTIs and NNRTIs, singularly or combined, are the most prevalent causes of HIV secondary drug resistance in Panama. 8 The 47 samples in this study were collected from Panama City, where ART has 7 Pingen M, Nijhuis M, Boucher C, Wensing A.
The Ages within this study's patient population ranged from 16 to 26 years: 96.0% of the cohort was ≤ 25 years old and all patients ≥ 25 years old (25, n = 2; 26, n = 2) had an HIV-negative test in the 3 years before diagnosis. However, the age range of patients was at the limit of WHO-TS feasibility: the mandatory age-eligibility criterion stipulates < 25 years. The period of sample collection was 2.5 years: WHO recommends only 12 months.
While ICGES received 100.0% of newly diagnosed HIV-positive patients from Panama City, identifying 47 age-eligible individuals in 12 months was difficult and was the reason for adapting the WHO-TS methodology to older patients and longer sampling. Panama has the second highest HIV prevalence rate in Central America (17) , but HIV infections are concentrated in specific groups (44) and absolute numbers of new HIVpositive patients from the general population attending ICGES were low.
Identifying sufficient numbers of eligible HIV-positive patients will be a problem faced by similar countries in Latin America, with small populations, low numbers of HIV infections, low prevalence, and concentrated epidemics. The WHO publication on WHO-TS (23) states: "generally no more than 50 individuals < 25 years of age, without previous pregnancies and ineligible for ART, were likely to be diagnosed with HIV . . . within 3-6 months, even in areas of high HIV prevalence." For these reasons, either WHO-TS HIV TDR studies are best applied only in populations or subpopulations with a high prevalence of HIV, or WHO could consider adapting survey guidelines to increase participation by small populations with a low prevalence of HIV and generalized epidemics.
These alterations may involve relaxing the < 25-year age criterion. In WHO-TS, patient age is an indicator of recent infection, and if some other marker of re- Total patients with TDR-associated mutations 2 1 0 0 Note: AZT: zidovudine, NRTI: nucleoside analog reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, M: male, F: female, . . . : no data, CK6: Combivir (lamivudine with zidovudine) begun 6 weeks before labor, CK8: Kaletra (lopinavir/ritonavir) begun 8 weeks before labor, none: no mutations observed, TDR: transmitted drug resistance, bold lettering: polymorphisms not associated with transmitted drug resistance, underlined bold lettering: mutations associated with transmitted drug resistance. a Medication applied refers to antiretroviral therapy provided to the infant from birth and to the mother during pregnancy. b The mother of this patient was a known HIV-positive patient who did not take antiretroviral therapy during her pregnancy. c These patients have died. WHO-TS methodology was designed to help developing countries assess HIV TDR economically. We suggest it is important that WHO consider alternative criteria for site selection and patient eligibility to maximize WHO-TS participation, especially in Latin American countries underrepresented in this program. There is some urgency in increasing participation, as future opportunities for WHO-TS may be limited: ART for preventing transmission is increasingly discussed (46) and, if adopted, wider uptake throughout the developing world will make it more difficult to identify ARV-naive patients.
This study also represents Panama's first molecular examination of IDR in 25 HIV-positive infants. Between 2007 and 2009, the overall prevalence of IDR was 12.0% (n = 3), the prevalence of IDR mutations against NRTIs was moderate (8.0%), and the prevalence of IDR was < 5.0% for NNRTIs and protease inhibitors.
Data from Panama' (17) and our data show two cases of HIV IDR, with one case of NRTI resistance (T215Y) and one case of NNRTI resistance (K103N). The mother of the K103N infant was a known HIV-positive patient of poor compliance who did not take ART prenatally.
Conclusion
The overall prevalence of HIV TDR was moderate. This fact, combined with known rates of HIV infection among adult Panamanians, suggests that it is important that more extensive surveys better identify factors associated with horizontal HIV TDR and assist Panama's Ministry of Health in choosing firstand second-line regimens. Applying WHO-TS to high-risk subpopulations in Panama may reveal a broader range of resistance mutations, while larger surveillance studies may more accurately indicate the prevalence of HIV TDR in the general population.
Some HIV-positive mothers in Panama transmit HIV and HIVDR to their infants. To better understand vertical infection and IDR, we also need new surveys among HIV-positive pregnant women and their newborns. This will require collection of sociodemographic data providing early warnings about mothers at increased risk of transmitting HIV, information about ART use by infants and their mothers before and during pregnancy, and introduction of genotyping tests at defined times during pregnancy and neonatal life. Establishing public health protocols in Panama whereby HIV-positive mothers and their newborns would be automatically subject to HIVDR analysis would be a useful collaboration between Panama's Ministry of Health, ICGES, and antenatal clinics. Finally, we recommend establishing WHO-TS guidelines specifically for assessing IDR.
Objetivo. Investigar la prevalencia de farmacorresistencia transmitida del VIH en adultos en Panamá mediante un estudio del umbral modificado de la Organización Mundial de la Salud (OMS) e investigar las tasas de resistencia inicial en lactantes seropositivos para el VIH en Panamá. Métodos. En el Instituto Conmemorativo Gorgas, en 47 adultos seropositivos al VIH se efectuó la genotipificación de las mutaciones asociadas con la farmacorresistencia transmitida en los genes de la transcriptasa inversa y la proteasa del VIH-1, según las directrices del estudio umbral de la OMS, modificadas para incluir a las personas ≤ 26 años de edad. Las tasas de prevalencia de las mutaciones farmacorresistentes contra tres clases de fármacos antirretroviral -inhibidores de la transcriptasa inversa análogos de nucleósidos, inhibidores de la transcriptasa inversa no análogos de nucleósidos e inhibidores de la proteasa-se clasificaron en bajas (< 5,0%), moderadas (5,0%-15,0%) o altas (> 15,0%). También se llevó a cabo genotipificación y se calcularon las tasas de prevalencia de las mutaciones causantes de farmacorresistencia en 25 lactantes. Resultados. En los adultos de Panamá la farmacorresistencia transmitida fue moderada: 6 de 47 adultos seropositivos para el VIH presentaron una o más mutaciones asociadas con farmacorresistencia transmitida. Las mutaciones farmacorresitentes de transmisión horizontal fueron moderadas para los inhibidores de la transcriptasa inversa análogos de nucleósidos y los inhibidores de la transcriptasa inversa no aná-logos de nucleósidos, y bajas para los inhibidores de la proteasa. En Panamá la transmisión vertical del VIH ha disminuido en el período 2002-2007, pero la prevalencia de la farmacorresistencia del VIH transmitida por vía vertical es moderada (12,0%) y está surgiendo como un problema debido a la cobertura antirretroviral incompleta durante el embarazo. Conclusiones. La prevalencia de farmacorresistencia transmitida del VIH observada en este estudio, junto con las tasas de infección por el VIH registradas en Panamá, indican que se necesitan estudios más amplios para determinar los factores de riesgo asociados con la transmisión de la farmacorresistencia del VIH. Deben establecerse directrices específicas del estudio del umbral de la OMS a fin de vigilar la transmisión vertical del VIH farmacorresistente.
VIH-1; resistencia a medicamentos; transmisión vertical de enfermedad infecciosa; inhibidores de proteasas; terapia antirretroviral altamente activa; Panamá. 
